Nociti, Viviana
 Distribuzione geografica
Continente #
NA - Nord America 5.159
EU - Europa 4.401
AS - Asia 3.664
SA - Sud America 742
AF - Africa 106
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 9
Totale 14.097
Nazione #
US - Stati Uniti d'America 5.053
DE - Germania 1.706
SG - Singapore 1.663
CN - Cina 921
SE - Svezia 751
BR - Brasile 601
FR - Francia 399
UA - Ucraina 354
VN - Vietnam 328
IT - Italia 318
GB - Regno Unito 216
IN - India 172
IE - Irlanda 170
FI - Finlandia 152
ID - Indonesia 122
RU - Federazione Russa 93
JP - Giappone 78
TR - Turchia 71
PL - Polonia 59
HK - Hong Kong 58
IQ - Iraq 50
AR - Argentina 45
CA - Canada 42
BD - Bangladesh 36
BE - Belgio 35
ZA - Sudafrica 35
MX - Messico 27
AT - Austria 26
NL - Olanda 26
CO - Colombia 20
EC - Ecuador 20
IR - Iran 19
VE - Venezuela 19
KR - Corea 18
SA - Arabia Saudita 18
CI - Costa d'Avorio 17
ES - Italia 17
MA - Marocco 15
UZ - Uzbekistan 14
AU - Australia 11
CL - Cile 11
UY - Uruguay 11
AZ - Azerbaigian 10
JO - Giordania 10
PK - Pakistan 10
PY - Paraguay 10
CH - Svizzera 9
IL - Israele 9
KE - Kenya 8
EG - Egitto 7
GR - Grecia 7
RO - Romania 7
A2 - ???statistics.table.value.countryCode.A2??? 6
CZ - Repubblica Ceca 6
DO - Repubblica Dominicana 6
JM - Giamaica 6
LT - Lituania 6
MD - Moldavia 6
MY - Malesia 6
TN - Tunisia 6
BG - Bulgaria 5
BY - Bielorussia 5
NP - Nepal 5
PH - Filippine 5
BO - Bolivia 4
CR - Costa Rica 4
DZ - Algeria 4
HU - Ungheria 4
KZ - Kazakistan 4
NO - Norvegia 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
TT - Trinidad e Tobago 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
BH - Bahrain 3
EU - Europa 3
HN - Honduras 3
HT - Haiti 3
NI - Nicaragua 3
OM - Oman 3
PS - Palestinian Territory 3
PT - Portogallo 3
QA - Qatar 3
AM - Armenia 2
AO - Angola 2
EE - Estonia 2
ET - Etiopia 2
GE - Georgia 2
KG - Kirghizistan 2
KH - Cambogia 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
MN - Mongolia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
SY - Repubblica araba siriana 2
Totale 14.075
Città #
Singapore 870
Chandler 758
Ashburn 587
San Jose 494
Jacksonville 248
Ann Arbor 191
San Mateo 178
Dublin 170
Beijing 168
Munich 159
New York 131
Los Angeles 120
Nürnberg 116
Nanjing 115
Ho Chi Minh City 111
Jakarta 111
Wilmington 105
Dearborn 101
Lauterbourg 101
Hanoi 93
Hefei 91
Woodbridge 78
Houston 71
Boston 67
Princeton 62
Helsinki 60
Tokyo 57
Moscow 55
Hong Kong 54
Milan 54
Marseille 50
Frankfurt am Main 49
Buffalo 46
Seattle 46
Bremen 45
Dallas 45
São Paulo 45
Izmir 44
Chicago 43
Norwalk 43
Redwood City 43
Nanchang 41
Rome 40
Lawrence 35
Brussels 33
Cattolica 32
Fairfield 29
Detroit 28
Warsaw 28
Santa Clara 27
Kent 24
Kraków 24
Mountain View 24
Shanghai 24
Kunming 23
Brooklyn 22
Hebei 22
Rio de Janeiro 22
University Park 22
Johannesburg 21
Paris 21
Shenyang 21
Boardman 20
Düsseldorf 20
Tianjin 20
Chennai 19
Jiaxing 19
Nuremberg 19
Atlanta 18
Belo Horizonte 18
Guangzhou 18
Haiphong 18
Abidjan 17
Baghdad 17
Orem 17
Da Nang 16
Seoul 16
Fremont 15
London 15
The Dalles 15
Portsmouth 14
Pune 14
Turku 14
Council Bluffs 13
Leawood 13
Manchester 13
San Francisco 13
Stockholm 13
Vienna 13
Ottawa 12
Redmond 12
Tashkent 12
Zhengzhou 12
Changsha 11
Falls Church 11
Amman 10
Baku 10
Jinan 10
Amsterdam 9
Denver 9
Totale 7.193
Nome #
Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis 264
Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab 253
Optical Coherence Tomography Advanced Parameters in Patients With Multiple Sclerosis: Ophthalmological and Neurological Assessments 250
pSTAT1, pSTAT3, and T-bet as markers of disease activity in chronic inflammatory demyelinating polyradiculoneuropathy. 244
CD8(+) T Cells in Facioscapulohumeral Muscular Dystrophy Patients with Inflammatory Features at Muscle MRI 238
T-bet, pSTAT1 and pSTAT3 expression in peripheral blood mononuclear cells during pregnancy correlates with post-partum activation of multiple sclerosis. 235
T-bet and pSTAT1 expression in peripheral blood mononuclear cells from coeliac disease patients: new markers of disease activity 219
Progressive ascending myelopathy: atypical forms of multiple sclerosis or what else? 195
The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing-remitting multiple sclerosis. 191
Multiple Sclerosis attacks triggered by hyperprolactinemia 191
Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease 186
The left parietal lobe plays a role in the pathogenesis of blepharospasm? 183
Pneumonia's link with the head and heart. 176
Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab 176
Migraine-like headache and status migrainosus as attacks of Multiple Sclerosis in a child. 175
Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients. 173
Circulating CD8+CD56-Perforin+ T cells are increased in Multiple Sclerosis patients 171
Somatosensory evoked potentials reflect the upper limb motor performance in multiple sclerosis. 170
Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients 169
Epstein-Barr virus antibodies in serum and cerebrospinal fluid from Multiple Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Amyotrophic Lateral 165
Type 1 immune response in progressive Multiple Sclerosis 164
A Case of Hemiabdominal Myoclonus 164
Demyelinating Encephalomyeloradiculitis with Balò-like lesions 163
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 163
Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment. 162
Movement disorders in multiple sclerosis: Causal or coincidental association? 160
CD4+pSTAT3+ and CD8+T-bet+ T cells accumulate in peripheral blood during NZB treatment 153
CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients 151
Serum lactate as a novel potential biomarker in multiple sclerosis 147
Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients 146
Increased CD4(+)CD25(+)Foxp3(+) T Cells in Peripheral Blood of Celiac Disease Patients: Correlation with Dietary Treatment. 145
IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis. 144
Brainstem and spinal cord involvement in a paraneoplastic syndrome associated with anti-Yo antibody and breast cancer. 142
The persistency of high levels of pSTAT3 expression in circulating CD4+ T cells from CIS patients favors the early conversion to clinically defined multiple sclerosis. 140
Pneumonia's link with the head and the heart 138
Chronic migraine-like headache caused by a demyelinating lesion in the brainstem 137
Depression in multiple sclerosis: effect of brain derived neurotrophic factor Val66Met polymorphism and disease perception 137
Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study 136
Breastfeeding and multiple sclerosis 135
Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis 135
Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion 134
Effects of rehabilitation treatment of the upper limb in Multiple Sclerosis patients and predictive value of neurophysiological measures 134
gc) Increased CD4+CD25+Foxp3+ T cells in peripheral blood of celiac disease patients: correlation with dietary treatment. 131
A Case of Hemiabdominal Myoclonus 130
Motor assessment of upper extremity function and its relation with fatigue, cognitive function and quality of life in multiple sclerosis patients 129
Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients 128
The Expanding Role of the Infectious Disease Expert in the Context of the MS Centre 127
Teaching NeuroImages: Autosomal dominant leukodystrophy in a sporadic case. 126
A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients 125
Tourettism in multiple sclerosis: a case report 122
Glioblastoma in multiple sclerosis: a case report 122
Coeliac disease presenting with acute disseminated encephalomyelitis. 121
Neurotriphic factor in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy 121
Monophasic demyelinating disease of the central nervous system associated with Hepatitis A infection 121
Case of postpartum Parsonage-Turner syndrome 121
Expression Profile of Long Non-Coding RNAs in Serum of Patients with Multiple Sclerosis. 119
Defining the disease course of TNFα blockers-associated Multiple Sclerosis 119
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 118
Coeliac disease presenting with acute disseminated encephalomyelitis 118
Multiple sclerosis attacks triggered by hyperprolactinemia 116
Leptin enhances the release of cytokines by peripheral blood mononuclear cells from relapsing multiple sclerosis patients 116
Liposome-based nanoparticles impact on regulatory and effector phenotypes of macrophages and T cells in multiple Sclerosis patients 115
The Impact of Neurogenic Lower Urinary Tract Symptoms and Erectile Dysfunctions on Marital Relationship in Men with Multiple Sclerosis: A Single Cohort Study 114
Regulatory T cells fail to suppress CD4(+)T-bet(+) T cells in relapsing multiple sclerosis patients 114
Response to the letter to the Editor for the manuscript “Sleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort study” by Tomoyuki Kawada 114
Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment 113
BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression 113
A unique case of multiphasic ADEM or what else? 113
Lower urinary tract disorders in multiple sclerosis patients: prevalence, clinical features, and response to treatments 113
A pilot study of lncRNAs expression profile in serum of progressive multiple sclerosis patients 110
Focal hyperhidrosis in tumefactive Multiple Sclerosis 109
Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems 109
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report 109
gc) T-bet and pSTAT-1 expression in PBMC from coeliac disease patients: new markers of disease activity. 108
Posterior reversible encephalopathy syndrome after intramuscular oxygen-ozone therapy 108
CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis 107
gc)Increased expression of T-bet in circulating B cells from a patient with multiple sclerosis and celiac disease 107
An atypical case of acute disseminated encephalomyelitis associated with cytomegalovirus infection 107
The predictive value of CSF multiple assay in multiple sclerosis: A single center experience 106
What do we know about the role of lncRNAs in multiple sclerosis? 106
Correction: BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression(PLoS ONE (2018) 1310 (e0206140) DOI: 10.1371/journal.pone.0206140) 105
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 105
pSTAT1, pSTAT3, and T-bet expression in peripheral blood mononuclear cells from relapsing-remitting multiple sclerosis patients correlates with disease activity 104
Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients 104
Evidence of involvement of leptin and IL-6 peptides in the action of interferon-beta in secondary progressive multiple sclerosis 103
Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta 102
Clinical characteristics, course and prognosis of spinal multiple sclerosis 102
Fingolimod vs dimethyl fumarate in multiple sclerosis 102
In vivo effect of Mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients 100
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 95
COVID-19 presenting as a non-arteritic anterior ischemic optic neuropathy 94
Neurosarcoidosis presenting as longitudinally extensive myelitis: Diagnostic assessment, differential diagnosis, and therapeutic approach 94
Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis 93
Exit strategies for “needle fatigue” in multiple sclerosis: a propensity score-matched comparison study 93
Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study 90
Neurologic Urinary Incontinence, Lower Urinary Tract Symptoms and Sexual Dysfunctions in Multiple Sclerosis: Expert Opinions Based on the Review of Current Evidences 88
Systematic assessment and characterization of chronic pain in multiple sclerosis patients 83
Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy 79
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 79
Treatment modifiers across different regimens of natalizumab treatment in MS: An Italian real-world experience 77
Totale 13.571
Categoria #
all - tutte 54.814
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.814


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021291 0 0 0 0 0 0 0 0 0 61 200 30
2021/2022959 98 78 18 120 29 38 17 141 48 55 130 187
2022/20232.007 224 283 164 319 121 276 101 183 233 31 53 19
2023/2024907 35 269 26 59 24 122 92 27 21 24 103 105
2024/20251.929 54 67 145 97 124 85 78 99 321 166 381 312
2025/20264.443 775 140 262 518 910 179 763 240 336 320 0 0
Totale 14.260